Application Note 205 Determination of Cefepime and Cefepime- Related Substances Using HPLC with UV Detection

Importance of the Topic

Cefepime, a fourth generation cephalosporin, plays a critical role in treating broad spectrum bacterial infections. Its strained beta lactam ring and structurally similar synthesis impurities require robust analytical methods to ensure purity and potency.

Objectives and Study Overview

This study presents optimized HPLC-UV methods for simultaneous determination of cefepime and related substances, comparing sterically selective and polar-embedded stationary phases. Modifications aim to reduce run time, improve resolution, and simplify assay protocols.

Instrumentation Used

• Dionex UltiMate 3000 LC system including SRD-3600 solvent rack, DGP-3600M pump, WPS-3000T autosampler, FLM-3100 or TCC-3200 column compartment, and VWD-3400 UV detector with 2.5 microliter flow cell.

Methodology

Mobile phase A comprised monobasic potassium phosphate buffer (5 mM, pH 5.0) with 6 or 10 percent acetonitrile; mobile phase B was 50/50 buffer/acetonitrile. Gradient conditions followed USP monograph or shortened runs. Columns evaluated were Acclaim 120 C18 (3 micron, 2.1×150 mm) and Acclaim PolarAdvantage under isocratic and gradient modes. Sample preparation included gravimetric dilution to 1.4 mg/mL cefepime in water, with autosampler temperature controlled at 4 °C.

Key Results and Discussion

• Under USP gradient, Acclaim 120 C18 achieved resolution >23 for primary related substance and >120 for secondary, with asymmetry 1.4 and over 9600 plates.
• Reducing acetonitrile in mobile phase A to 6 percent baseline-resolved impurity F. The PolarAdvantage column further improved peak shape (asymmetry ~1.1) and resolution (~4.9).
• Shortened gradient protocols cut run times by over 20 minutes while still meeting USP criteria, with retention time and area precision below 0.1 percent RSD.
• Isocratic assays using 6 and 10 percent acetonitrile showed excellent linearity (r2>0.9998), low LOD (0.03–0.06 microgram/mL), and LOQ (0.12–0.20 microgram/mL).
• Sample stability tests revealed no significant degradation when stored at 4 °C or -19 °C for 96 hours. Room temperature storage led to a 2.9 percent loss at 24 hours and 12 percent at 96 hours.

Benefits and Practical Applications

These optimized methods deliver faster analysis, reduced solvent consumption, and simplified mobile phase preparation. Enhanced resolution supports accurate impurity profiling in quality control laboratories. Single-phase assay protocols streamline purity tests and concentration determinations.

Future Trends and Opportunities

Integration of mass spectrometry detection, transition to UHPLC formats for even faster separations, automated online buffer preparation, and expanded applicability to other beta-lactam antibiotics are promising avenues.

Conclusion

The Acclaim 120 C18 and PolarAdvantage columns enable rapid, high-resolution HPLC-UV methods for cefepime and related substances, offering robust quantification and improved throughput. Adherence to temperature control and sample handling guidelines ensures accurate stability assessments.

References

1. Mutnick AH et al. Journal of Antimicrobial Chemotherapy 2004, 53:290–296.
2. Rabouan-Guyon SM et al. International Journal of Pharmaceutics 1997, 154:185–190.
3. El-Shaboury SR et al. Journal of Pharmaceutical and Biomedical Analysis 2007, 45:1–19.
4. Yahav D et al. Lancet Infectious Diseases 2007, 7:338–348.
5. Sprauten PF et al. Antimicrobial Agents and Chemotherapy 2003, 47:1991–1994.
6. Dionex Corporation. Application Note 199, 2008.
7. United States Pharmacopeia 30–NF 25, 2007.
8. European Pharmacopeia, Fourth Edition, 2002.
9. Evagelou V et al. Journal of Pharmaceutical and Biomedical Analysis 2003, 31:1119–1128.
10. Pistos C et al. Journal of Pharmaceutical and Biomedical Analysis 2005, 39:438–443.